Guangdong Hybribio Biotech Co.,Ltd.

XSEC:300639 Stock Report

Market Cap: CN¥4.1b

Guangdong Hybribio BiotechLtd Past Earnings Performance

Past criteria checks 0/6

Guangdong Hybribio BiotechLtd has been growing earnings at an average annual rate of 3.8%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 11.7% per year.

Key information

3.8%

Earnings growth rate

2.5%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate11.7%
Return on equity-9.8%
Net Margin-34.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guangdong Hybribio BiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:300639 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24864-29490699
30 Jun 24907-59597111
31 Mar 2498561505123
31 Dec 231,104140522136
30 Sep 232,189410677190
30 Jun 233,361871761238
31 Mar 234,3881,292861256
01 Jan 235,5971,7261,098247
30 Sep 224,9401,693927195
30 Jun 224,2171,439888146
31 Mar 223,5741,180830118
01 Jan 222,673852633115
30 Sep 212,429736616108
30 Jun 212,14862559196
31 Mar 211,81451554886
31 Dec 201,35436346572
30 Sep 201,12931642261
30 Jun 2091821640159
31 Mar 2074215037161
31 Dec 1972914738657
30 Sep 1969314137655
30 Jun 1964812835552
31 Mar 1961011934055
31 Dec 1858011432746
30 Sep 1854810730741
30 Jun 1851810227652
31 Mar 184999628134
31 Dec 174799326734
30 Sep 174558926324
30 Jun 17431802740
31 Mar 17411772600
31 Dec 16398762560
31 Dec 15345652270
31 Dec 14264631520
31 Dec 13183291130

Quality Earnings: 300639 is currently unprofitable.

Growing Profit Margin: 300639 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300639 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.8% per year.

Accelerating Growth: Unable to compare 300639's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300639 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 300639 has a negative Return on Equity (-9.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:22
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangdong Hybribio Biotech Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hanqing ZhuGuosen Securities Co., Ltd.
Jiaxi XuIndustrial Securities Co. Ltd.
Jiaqi ZhuZhongtai Securities Co. Ltd.